Table 2 Number of patients with CHD with appropriate assessment and treatment with specified drugs for secondary prevention at baseline and after 1 year of follow-up
Number of observationsNumber (%)Estimated intra-cluster correlation coefficients* (SE)OR (95% CI)*p Value
InterventionControl
Risk factors
BP measured
    Baseline1012363 (81.8)460 (81.0)
    Follow-up1058446 (99.1)514 (84.5)0.1259 (0.0476)22.61 (6.47 to 70.13)<0.0001
Cholesterol measured
    Baseline892228 (51.8)350 (77.4)
    Follow-up1059333 (74.0)403 (66.2)0.1271 (0.0487)1.21 (0.71 to 2.08)0.4813
Smoking status recorded
    Baseline1045168 (38.0)197 (32.7)
    Follow-up1059421 (93.6)273 (44.8)0.0773 (0.0333)33.96 (14.49 to 79.62)<0.0001
BMI measured or weight checked
    Baseline1059189 (42.2)220 (36.0)
    Follow-up1059396 (88.2)281 (46.1)0.0125 (0.0412)10.14 (4.99 to 20.55)<0.0001
Risk factor management
BP<140/85 mm Hg
    Baseline1004184 (43.1)246 (42.6)
    Follow-up962250 (56.1)223 (43.2)0.0002 (0.0034)1.61 (1.22 to 2.13)0.0113
Cholesterol<5 mmol/l
    Baseline785202 (60.5)255 (56.5)
    Follow-up735249 (74.3)254 (63.5)0.1115 (0.0214)1.58 (1.05 to 2.37)0.0314
Prescribing of secondary prevention medicines
Lipid-lowering medication
    Baseline1080230 (49.9)280 (45.2)
    Follow-up1080275 (59.6)322 (52.0)0.0051 (0.0079)1.99 (1.06 to 3.74)0.0281
Aspirin
    Baseline1080300 (65.1)388 (62.7)
    Follow-up1080314 (68.1)411 (66.4)0.0021 (0.0165)1.08 (0.84 to 1.40)0.5502
Beta-blocker†
    Baseline586110 (44.2)122 (36.2)
    Follow-up586125 (50.2)141 (41.8)0.0001 (0.0024)1.43 (1.19 to 1.99)0.0354
ACE inhibitor†
    Baseline48984 (39.4)117 (42.4)
    Follow-up489103 (48.4)140 (50.7)0.0179 (0.0194)0.97 (0.68 to 1.43)0.9301
  • Values are numbers (percentages) unless stated otherwise.

  • BMI, body mass index; BP, blood pressure.

  • *Values adjusted for baseline, age, gender and practice. †Patients with past history of myocardial infarction only.